Literature DB >> 18328427

Yes and PI3K bind CD95 to signal invasion of glioblastoma.

Susanne Kleber1, Ignacio Sancho-Martinez, Benedict Wiestler, Alexandra Beisel, Christian Gieffers, Oliver Hill, Meinolf Thiemann, Wolf Mueller, Jaromir Sykora, Andreas Kuhn, Nina Schreglmann, Elisabeth Letellier, Cecilia Zuliani, Stefan Klussmann, Marcin Teodorczyk, Hermann-Josef Gröne, Tom M Ganten, Holger Sültmann, Jochen Tüttenberg, Andreas von Deimling, Anne Regnier-Vigouroux, Christel Herold-Mende, Ana Martin-Villalba.   

Abstract

Invasion of surrounding brain tissue by isolated tumor cells represents one of the main obstacles to a curative therapy of glioblastoma multiforme. Here we unravel a mechanism regulating glioma infiltration. Tumor interaction with the surrounding brain tissue induces CD95 Ligand expression. Binding of CD95 Ligand to CD95 on glioblastoma cells recruits the Src family member Yes and the p85 subunit of phosphatidylinositol 3-kinase to CD95, which signal invasion via the glycogen synthase kinase 3-beta pathway and subsequent expression of matrix metalloproteinases. In a murine syngeneic model of intracranial GBM, neutralization of CD95 activity dramatically reduced the number of invading cells. Our results uncover CD95 as an activator of PI3K and, most importantly, as a crucial trigger of basal invasion of glioblastoma in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18328427     DOI: 10.1016/j.ccr.2008.02.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  132 in total

1.  NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression.

Authors:  Feiyan Liu; Kankana Bardhan; Dafeng Yang; Muthusamy Thangaraju; Vadivel Ganapathy; Jennifer L Waller; Georgia B Liles; Jeffrey R Lee; Kebin Liu
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

Review 2.  Pathway inhibition: emerging molecular targets for treating glioblastoma.

Authors:  Wolfgang Wick; Michael Weller; Markus Weiler; Tracy Batchelor; Alfred W K Yung; Michael Platten
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

Review 3.  Regulation of CD95/Fas signaling at the DISC.

Authors:  I N Lavrik; P H Krammer
Journal:  Cell Death Differ       Date:  2011-11-11       Impact factor: 15.828

Review 4.  Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.

Authors:  Wolfgang Wick; Antje Wick; Markus Weiler; Michael Weller
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

5.  Cross-talk between receptor tyrosine kinase and tumor necrosis factor-α signaling networks regulates apoptosis but not proliferation.

Authors:  Elsa M Beyer; Gavin MacBeath
Journal:  Mol Cell Proteomics       Date:  2012-02-08       Impact factor: 5.911

6.  Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts.

Authors:  Isabell Lang; Andrea Fick; Viktoria Schäfer; Tina Giner; Daniela Siegmund; Harald Wajant
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

7.  A link between smooth muscle cell death and extracellular matrix degradation during vascular atrophy.

Authors:  Richard D Kenagy; Seung-Kee Min; Eileen Mulvihill; Alexander W Clowes
Journal:  J Vasc Surg       Date:  2011-04-14       Impact factor: 4.268

8.  The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration.

Authors:  Yun-Ju Lai; Victor T G Lin; Ying Zheng; Etty N Benveniste; Fang-Tsyr Lin
Journal:  Mol Cell Biol       Date:  2010-09-27       Impact factor: 4.272

Review 9.  Life and death by death receptors.

Authors:  Maria Eugenia Guicciardi; Gregory J Gores
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

Review 10.  Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy.

Authors:  Fei Yi; Nicholas Frazzette; Anthony C Cruz; Christopher A Klebanoff; Richard M Siegel
Journal:  Trends Mol Med       Date:  2018-06-04       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.